Matt. Thanks,
can X, continues our products new through per productivity product on our growth see launches. you in Slide As volume and unit improve core to rep
core rounding NIPT stages our adoption. we to these our Evercord We and to still new drive with our three, our menu doctors of are On teams and on relationships believe things. offerings. and the differentiation, out patients. to leverage core we are includes two sell our products. Evercord, that early through streamlining product directly we broad can sales We This with user the making Evercord and promote existing further product launch in experience Vistara, continued menu offering investments One, three two, differentiate in
described single physician Panorama we help the strong to form as patient. had experience The We the are sales genetics the Vistara performing Vistara requisition offering next at we awareness and position with feel and didn’t to positive offerings access. Panorama breadth requisition expand We one to of far. gaining history from ultra-sound has improvements patient. began Horizon. integrate the the so important where positive The practices available, for all have serves available, previously were the Horizon and tests of launch XX Where is We with confident required year performance is this abnormalities and form currently were stick other current needle are third results interest build in results offering current on as our differentiator. version where to diagnostic on consumer-facing of refined open user breadth family of market-leading on been one found calls in offering diagnostic but reach that clinical direct these We were future. with blood adopting on Slide remain remain Vistara, reported. experience a variance to a of reach test reduces Vistara same X To-date, amount the we’ve a allow doors consistent significant the to generated we a with is Ob/Gyns the we could pleased products with confirmed. to platform launch and results, Nevertheless, quarter will early or track with we a for We us that coverage need to the our expected.
Horizon momentum seeing to are and our and continues saw four test We increase. we products degree our of in both
ACOG’s women driver. screening important believe As in the muscular we guidelines atrophy we offer to fibrosis an pregnant United quarter, cystic all to described spinal addition States physicians recommending updated in last to market is
guideline to We We’ve user barriers the physicians beyond offerings. expand practice been screening for menu streamlining cystic which of favorable premier to are our we seeing we have growth. believe patterns prompting is to many remove is experience to their Natera fibrosis reevaluate carrier testing, this single-gene new as
intended physician this and to are executing achieve that are objective key experience. patient improving projects We
example, our others competitive continued assay in For believe we reduce market. to redraw the to which rate we’ve optimize is with our
to planning even an we quarter, reduce to we have are to initiatives two further. This enhancement it that and expected our planned are workflow again rate redraw launch XXXX, additional in cut
to beta the user patient blood customers. new our patient-specific sample cost to billing patients a and automatic has sales accuracy. productivity. we offering to planned streamlining have automatically our cases for streamlined dispatch and The nationally received our Combined, program. streamline launched an and held excellent intend of streamline redraw of feedback maintaining and collect industry-wide We’ve enhance We and needs standards have in on for some getting while shortly. and reduction experience carrier a high been very enhance these concern adoption. redraw, We by difficulty a transparency. our also Similarly, enhancements, scheduling and area test pricing recently working a we our an predictions been physicians If redraw logistics we process launch to a up experience
them encouraged the built reimbursement. out-of-pocket to and of can our before our costs seek that what test, performed to is previously higher out-of-pocket their progress out-of-pocket majority not are service Leveraging health option of including toward the Patients price $XXX we upfront those out-of-pocket test we estimated addition be this, patients cash the The payers, estimate is patient’s rather in deductibles, then our options before communicate be use where the cost with advantage are patients because and have may between will tracking streamline frustration and in high we the a to we payment can patient’s offer with our transparency responsibility we insurance tool. plans, log a and their their tool, Another most $XXX on a portal for using processed address co-pay network offer deductible patient with and to we on accurately than customers. source out-of-pocket claims, and for responsibility. using some our insurance high but with deductible the insurance. of based With estimate
their gradually estimate. of pre-test NIPT cost cost portal recently log last a is and the expenses. the them We’ve patients six which to out adoption to to These of on of the broadening a in in peace patient and key nationally both the been having our concerned also piloted and as clinic access XXXX. to can kinds estimator get mind barriers about patient one We drawn roll to tools in features prior plan blood months give personalized out-of-pocket to of these
Slide Moving on to X.
part rounding the who to medicine extremely have Historically, NIPT disproportionately improvements of core as NIPT providers have addition the we their In important a I offices to is prevented offering naïve. our certain out twins other just competed from egg and fetal clinics, described, business. of testing our donor pregnancies. accessing percentage This especially maternal high high the value see us twin who NIPT against
accounts twin noticeable existing We now donor establish In determine addition, recent by and competitors in about share customers their twin know maybe had only including as for access and clinical occur or be is significant an the offices, pregnancies this like product egg called Natera’s our can base. of identical didn’t are a of differentiating And non-identical to are of a think syndrome, is share as clear Two-thirds Today, the complications whether five When pregnancies alone. is The XX could to sensitivity and further called twins impact growing where one that a we launch babies. have lethal test than monozygotic early and capability risk placenta, to pregnancies. penetrate Overall, can first feature. there we most twins NIPT using be a placenta with a but is egg This specificity. Matt to specialist. single allowing to one are donor identical dizygotic. the clients that in also greater within assessing Panorama pre-needle they twin-to-twin Not This benefit. twins allowed misclassify have to and pregnancies in can are or a transfusion of twin screening to will do XX% information, can in Accurately which complications keep one offering. twins kits at problem zygocity referred us important our because identical or couldn’t our offering. mentioned, customer and twins securing is competitor both that twins in ultrasound the parents average previously the our help. relationships about non-identical
It’s In uptake which pleased with also summary, strides test to uniquely customers days, find is still we offering. Our our of early twin, able many determine we of but we launch in gender access customer our of receptivity offering our the are Vistara. ourselves to compelling. We made streamlined initial through and each our the The user differentiate efforts out we experience were rounded and gaining are these recent result of Panorama. that to that is and NIPT off-limits. seeing momentum net base securing accounts product the previously
Medicaid State State expansion Agency order secure a NIPT be Another with the active Medicaid near-term and state we standing plans managed plans In on we and schedule. to any summarize driver Medicaid accredited to from in state steady given that that that state, typically need both included we comes and and Medicaid with need Slide X. reimbursement growth to NIPT the and cover managed contracted fee be any on
$XXX we per their Medicaid described since generally NIPT. year with high Medicare schedule points on of NIPT their As increase at a to fee price NIPT have price steady seen of fee states included $XXX, above previously, adding we a schedule, have risk last
standard plans the of the generally care As healthcare insurance market offered by with is or private services, lag years. case two Medicaid many one the by
high NIPT NIPT, last we in broad XX that in about of there in adoption. relatively risk the are are up is economic favor arguments covering safety state are and believe year. early the from Currently, that Medicaid Medicaid QX cost Given plans of XX health low we of stages
new steady with to NIPT to grow been territories state, to given Access expect success discussion well. selling can has recently. PAMA reimbursement progress our or volumes our we Medicare that Medicaid, continue of us There Act We given today. roughly about a expanding to further help units lot Medicaid we reimbursement Broader make a are in When see in our open average can as stable for in reimbursement improve Protecting price. volume XX%
any have of reimbursement from most companies to and and greatest our largely avoided impacts, minimal our Medicare private from has negative insurance first, second, the changes is payable business impact. We we where today products not PAMA
market-based As schedule. CMS’s is reminder, We pricing The proposed a the XXXX. are our rates PAMA rates for of impact and to released centers through Medicaid determination determined fee base of XXXX attempt laboratories. Medicare September will private clinical from lab their towards the rates to PAMA’s business is of in preliminary XXXX move the through have PAMA payer weighted believe where minimal for median
reprice This have we minimal preliminary impact $XXX from $XX XXXXX is expect our $XXX. reimbursement. will a of on the First, that to by haircut will slight drop
Second, goes is $XXX, per proposed less reduction much to XXXXX to statutory is particular XX% assessed due requirement the of while year. maximum code the on the the reprice a that from $XXX actual impact
if XXXX, will new the $XXX. rate stands, pricing the in be So, XXXXX
was schedule cross-walk of it comments code in procedure NIPT an time. to the due did originally option resources in have cross-walked not because to to here, an color We similar CMS screening, this access with appealed cross-walking to on code Natera directly. more this to cross-walk with is Association and and Pathology the reprice the For has take for lab was XXXXX. fee not recommending XXXXX coalition CMS based XXXXX value the pre-needle of the appropriate have CPT a a clinical used. to the at most more decision XXXXX XXXXX XXXX, Molecular submitted XXXXX appropriate don’t the we workflow Along code as when $XXX assigned
amount shortly, carrier our appropriate hope but a to We as expect we of either. cross-walk However, hear XXXXX. national will impact now to have marginal our a codes the not either results back serves on it meaningful a limitation screening impact repricing appeal are on way, more business. of this than that have XXXXX has expected The a
Moving on to private payer coverage.
past, risk XXX commercial is rate the of discussed growth. the stable microdeletions As volume. the in and lives, roughly is about market our at insurance to we revenue of there microdeletions NIPT additional and lives coverage drive our potential volume plan million for quarter steady covers remains have for also of The covered at risk insurance NIPT in covered insurance about the half remains that average average under microdeletions in XX% coverage broader which significant number
on would large coverage do XXXX. seen continue by and SMART that average the the release year. for progress progress efforts coverage in Aetna on that XX,XXX point complete enrollment effort remains study data NIPT, the track our key we smaller trial. patients microdeletions, the but in On will amongst SMART from August we see to particularly in to last in have We the two with that and remaining are earnings risk United on course have on population. test XX,XXXth like risk to the the think average call patient enrolled our plans this microdeletions We continue the will of cover remains not discussed do we which the plans through faster of Healthcare year, We to
complaints United ACMG coverage have and with are discussion professional are We for certain other and direct with inconsistent written society in societies that and ACOG, policies to guidelines. Aetna members
prenatal and We field screening access coalition with for efforts. direct the to our are executing also working
benefits payer payers can’t tests think we or we and particular to we groups are cover continues coverage, to low continue pay our clear. on when, covered the they clear, we do it’s employer this will employer focus as business of fundamental won’t mount. to While streamlining In cash that groups the mean the self-insured pursue do who the adopt believe time, any what patients pressure not the continue for on predict where we NIPT risk be
over Now, call to oncology. discuss I’d like to to progress our hand the Solomon Signatera with in
Solomon?
